


Buy EUR 40.00 (EUR 42.00) Price EUR 22.50 Upside 77.8 %	Value Indicators: EUR DCF: 40.00	Warburg ESG Risk Score: 2.0 ESG Score (MSCI based): 3.0 Balance Sheet Score: 3.0 Market Liquidity Score: 0.0	Description: Investment company focused on Mittelstand manufacturing technology companies
	Market Snapshot: EUR m Market cap: 98.9 No. of shares (m): 4.4 EV: 179.2 Freefloat MC: 44.1 Ø Trad. Vol. (30d): 8.65 th	Shareholders: Freefloat 44.60 % PartnerFonds AG 41.90 % Kreissparkasse Biberach 13.50 %	Key Figures (WRe): 2022e Beta: 1.5 Price / Book: 0.9 x Equity Ratio: 41 % Net Fin. Debt / EBITDA: 1.6 x Net Debt / EBITDA: 1.8 x

Another quarter of double-digit organic growth

- A strong set of 9M figures was reported by Blue Cap last week as sales grew 39% to EUR 265m. While the acquisitions of H+E (March 21), HY-LINE (Sept 21) and Transline (March 22) contributed to this performance, the strong underlying performance of its plastic divisions led to organic sales growth of 21.5% in the first nine months. Despite the increasing economic challenges, organic sales still grew more than 20% in Q3.
- Adj. EBITDA grew by as much as 61% yoy to EUR 25.6m in the first nine months, equivalent to a margin of 9.6%. While the adj. EBITDA margin declined to 8.6% in Q3 from 10.2% in H1, the margin is still 80bp higher than the prior year and represents a rate of organic growth in the high teens.
- Management reiterated its FY guidance for sales of EUR 335-350m and an adj. EBITDA margin of 8-9%. We still consider this guidance as conservative as even the top end of the guidance implies a decline in organic sales growth of more than 15pp in Q4 compared to the Q3 growth trend. While we still expect Blue Cap to beat its margin guidance, we have slightly trimmed our estimates to reflect the increased energy costs.
- Although it is early days, we expect a 5% sales decline in 2023 as Blue Cap will feel the negative impact of the economic headwinds while facing a very tough comparison base. In 2022 conpearl benefitted from a large logistic order and management doesn't expect additional business from this customer before 2024. Furthermore, the resolution of the semiconductor supply bottleneck has accelerated growth at HY Line substantially. Transline, the translation business, has already seen the first signs of project postponement in Q3. On the other hand, the ongoing pass-through of cost increases should counterbalance some of these headwinds. The automotive business (H+E) should hold up better than in previous recessions, as volumes in the car industry have been constrained by the semi-shortage for most of the post-COVID recovery. Furthermore, the continued push for product innovation should bolster sales. In light of the expected sales decline, we also assume a slight margin contraction. We expect Blue Cap's growth to resume in 2024, assuming a more benign economic environment.
- We slightly trim our DCF-based fair value to EUR 40 to reflect the cut in our earnings estimates. We confirm our Buy rating as, despite the cut in our estimates, the valuation is highly attractive. Furthermore, the recession should lead to more attractive valuations for takeovers.

Changes in Estimates:				Comment on Changes:			
FY End: 31.12. in EUR m	2022e (old)	+ / -	2023e (old)	+ / -	2024e (old)	+ / -	
Sales	348.0	0.0 %	340.0	-2.9 %	357.0	-2.9 %	<ul style="list-style-type: none"> Margin pressure due to rising energy prices. Assumed recession to lead to sales and margin decline in 2023
EBITDA adj.	34.0	-2.8 %	32.4	-7.7 %	36.4	-5.2 %	
EBT	22.5	-4.2 %	7.2	-6.3 %	11.0	3.3 %	
EPS	3.58	-4.2 %	1.14	-6.1 %	1.75	2.9 %	




Rel. Performance vs Scale All	
1 month:	8.4 %
6 months:	12.9 %
Year to date:	9.0 %
Trailing 12 months:	16.5 %

Company events:	


FY End: 31.12. in EUR m	CAGR (21-24e)	2018	2019	2020	2021	2022e	2023e	2024e
Sales	9.0 %	176.0	225.7	233.0	267.3	348.0	330.0	346.5
Change Sales yoy		24.1 %	28.2 %	3.2 %	14.7 %	30.2 %	-5.2 %	5.0 %
EBITDA adj.		8.6	14.3	17.6	24.6	33.0	30.0	34.5
Margin	2.6 %	4.9 %	6.4 %	7.6 %	9.2 %	9.5 %	9.1 %	10.0 %
EBIT adj.		2.9	6.4	8.9	13.3	17.9	16.4	20.8
Margin	6.4 %	1.6 %	2.9 %	3.8 %	5.0 %	5.1 %	5.0 %	6.0 %
EBT		12.1	2.4	17.5	5.1	21.5	6.7	11.3
Net income	15.5 %	12.5	2.8	16.6	5.2	15.1	4.7	7.9
EPS	13.2 %	3.14	0.71	4.15	1.24	3.43	1.07	1.80
EPS adj.		1.26	1.15	1.51	2.53	2.73	2.50	3.24
DPS	12.2 %	0.75	0.75	1.00	0.85	1.00	1.00	1.20
Dividend Yield		3.7 %	4.3 %	5.7 %	3.2 %	4.4 %	4.4 %	5.3 %
FCFPS		-1.03	-1.15	1.08	1.54	6.69	4.29	4.01
FCF / Market cap		-5.1 %	-6.6 %	6.2 %	5.8 %	29.7 %	19.1 %	17.8 %
EV / Sales		0.7 x	0.6 x	0.5 x	0.7 x	0.5 x	0.5 x	0.4 x
EV / EBITDA adj.		13.6 x	9.9 x	6.8 x	7.6 x	5.4 x	5.5 x	4.4 x
EV / EBIT adj.		40.7 x	22.0 x	13.5 x	14.1 x	10.0 x	10.0 x	7.2 x
P / E adj.		16.0 x	15.2 x	11.5 x	10.6 x	8.2 x	9.0 x	6.9 x
FCF Potential Yield		18.4 %	10.9 %	27.8 %	13.4 %	21.6 %	16.0 %	19.7 %
Net Debt		36.8	72.6	50.8	76.3	80.3	65.4	51.8
ROE		20.2 %	4.2 %	22.5 %	5.9 %	15.2 %	4.5 %	7.4 %
ROCE (NOPAT)		16.2 %	4.1 %	13.9 %	3.6 %	8.6 %	2.8 %	4.8 %
Guidance:		2022: sales of EUR 335m to EUR 350m and adj. EBITDA margin of 8.0% to 9.0%						

Sales development
in EUR m




Source: Warburg Research

Sales by regions
2021; in %



Source: Warburg Research

adj. EBITDA development
in EUR m



Source: Warburg Research


Company Background

- Blue Cap is a Munich-based investment company with a focus on Mittelstand niche suppliers with revenue volumes of EUR 30-80m
- The company only invests in well-positioned B2B companies that find themselves in a so-called "special situation"
- Such "special situations" include e.g. an unresolved succession issue, management problems or financing difficulties. Only companies with an intact core business and substantial growth potential are acquired
- Today, Blue Cap holds operative investments in technological sectors such as plastics, adhesives & coatings, production technology, business services, electronics and medtec.

Competitive Quality


- Blue Cap is headed by management with extensive private equity- and restructuring experience.
- All subsidiaries operate autonomously and pursue independent strategies, supported by the know-how of the Holding's management
- New investments can be acquired from a network of banks, financial service providers, consultancies, auditors and tax advisors. This safeguards access to further growth.
- With its focus on small Mittelstand companies with revenue of EUR 30-80m, Blue Cap is targeting a smaller size than most competitors. This clearly improves the choice of attractive investments
- There is now pre-defined holding period. Thus Blue Cap remains invested as long as it remains the "best owner" of the business.

EBIT development
in EUR m




Source: Warburg Research

Sales by segments
2021; in %



Source: Warburg Research

Net income development
in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period			Transitional period										Term. Value
	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	
Sales	348.0	330.0	346.5	363.8	371.1	378.5	386.1	395.7	403.7	411.7	420.0	428.4	436.9	
Sales change	30.2 %	-5.2 %	5.0 %	5.0 %	2.0 %	2.0 %	2.0 %	2.5 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %
EBIT	22.3	7.4	11.8	21.8	24.1	26.5	29.0	29.7	30.3	30.9	31.5	32.1	32.8	
EBIT-margin	6.4 %	2.2 %	3.4 %	6.0 %	6.5 %	7.0 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	
Tax rate (EBT)	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	
NOPAT	15.6	5.2	8.3	15.3	16.9	18.5	20.3	20.8	21.2	21.6	22.0	22.5	22.9	
Depreciation	22.8	21.0	21.3	15.3	14.8	15.1	13.5	13.9	14.1	14.4	14.7	15.0	15.3	
in % of Sales	6.6 %	6.4 %	6.2 %	4.2 %	4.0 %	4.0 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	
Changes in provisions	0.0	0.0	0.0	1.2	-0.5	-0.6	-0.6	-0.6	-0.6	-0.7	-0.3	0.1	0.1	
Change in Liquidity from														
- Working Capital	-0.3	-2.5	2.3	3.1	1.8	1.8	1.9	2.2	1.2	1.2	1.2	1.3	1.3	
- Capex	8.8	9.3	9.3	12.7	13.0	13.2	13.5	13.9	14.1	14.4	14.7	15.0	15.3	
Capex in % of Sales	2.5 %	2.8 %	2.7 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	3.5 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	30.0	19.3	18.0	16.0	16.4	18.1	17.8	18.0	19.4	19.7	20.5	21.4	21.8	22
PV of FCF	27.9	16.5	14.1	11.5	10.8	10.9	9.9	9.2	9.1	8.5	8.1	7.7	7.2	106
share of PVs	22.68 %			36.07 %										41.25 %

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	25.00 %	Financial Strength	1.60
Cost of debt (after tax)	2.8 %	Liquidity (share)	1.60
Market return	8.25 %	Cyclicality	1.60
Risk free rate	2.75 %	Transparency	1.60
		Others	1.10
WACC	8.95 %	Beta	1.50

Valuation (m)

Present values 2034e	151		
Terminal Value	106		
Financial liabilities	143		
Pension liabilities	9		
Hybrid capital	0		
Minority interest	5		
Market val. of investments	33		
Liquidity	41	No. of shares (m)	4.4
Equity Value	176	Value per share (EUR)	40.00

Sensitivity Value per Share (EUR)

Beta	WACC	Terminal Growth							Beta	WACC	Delta EBIT-margin						
		1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %			-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.74	10.0 %	31.33	31.84	32.38	32.96	33.57	34.22	34.91	1.74	10.0 %	22.51	25.99	29.48	32.96	36.44	39.92	43.40
1.62	9.5 %	34.30	34.90	35.55	36.24	36.98	37.77	38.62	1.62	9.5 %	25.10	28.82	32.53	36.24	39.95	43.67	47.38
1.56	9.2 %	35.92	36.58	37.30	38.06	38.87	39.75	40.69	1.56	9.2 %	26.53	30.38	34.22	38.06	41.90	45.74	49.58
1.50	9.0 %	37.65	38.38	39.16	40.00	40.91	41.88	42.93	1.50	9.0 %	28.07	32.05	36.02	40.00	43.98	47.96	51.94
1.44	8.7 %	39.49	40.30	41.17	42.09	43.10	44.18	45.35	1.44	8.7 %	29.72	33.84	37.97	42.09	46.22	50.35	54.47
1.38	8.5 %	41.47	42.36	43.32	44.35	45.46	46.67	47.99	1.38	8.5 %	31.50	35.78	40.06	44.35	48.63	52.92	57.20
1.26	8.0 %	45.87	46.96	48.15	49.43	50.82	52.35	54.02	1.26	8.0 %	35.50	40.14	44.79	49.43	54.07	58.72	63.36

- For the Group, growth at BSP level is expected.
- The target EBIT margin is derived from an estimate of the margin potential of the individual firms.
- In perpetuity, a comparatively low growth rate of just 1.5% is modelled.
- We included our 2023 SOTP estimate of Inheco in the model

Valuation	2018	2019	2020	2021	2022e	2023e	2024e
Price / Book	1.2 x	1.0 x	0.9 x	1.2 x	0.9 x	0.9 x	0.9 x
Book value per share ex intangibles	15.13	15.05	19.58	13.43	16.03	16.30	17.14
EV / Sales	0.7 x	0.6 x	0.5 x	0.7 x	0.5 x	0.5 x	0.4 x
EV / EBITDA	5.5 x	9.5 x	3.5 x	7.4 x	4.0 x	5.8 x	4.6 x
EV / EBIT	8.6 x	33.1 x	6.0 x	31.3 x	8.0 x	22.2 x	12.8 x
EV / EBIT adj.*	40.7 x	22.0 x	13.5 x	14.1 x	10.0 x	10.0 x	7.2 x
P / FCF	n.a.	n.a.	16.1 x	17.4 x	3.4 x	5.2 x	5.6 x
P / E	6.4 x	24.6 x	4.2 x	21.5 x	6.6 x	21.0 x	12.5 x
P / E adj.*	16.0 x	15.2 x	11.5 x	10.6 x	8.2 x	9.0 x	6.9 x
Dividend Yield	3.7 %	4.3 %	5.7 %	3.2 %	4.4 %	4.4 %	5.3 %
FCF Potential Yield (on market EV)	18.4 %	10.9 %	27.8 %	13.4 %	21.6 %	16.0 %	19.7 %

*Adjustments made for: -

Company Specific Items	2018	2019	2020	2021	2022e	2023e	2024e
Net Asset Value EURm	n.a.	141.2	153.9	172.8	168.0	175.0	190.0
Net Asset Value pro Aktie	n.a.	35.48	38.58	39.30	38.22	39.81	43.00

Consolidated profit & loss

In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Sales	176.0	225.7	233.0	267.3	348.0	330.0	346.5
Change Sales yoy	24.1 %	28.2 %	3.2 %	14.7 %	30.2 %	-5.2 %	5.0 %
Increase / decrease in inventory	1.4	-2.1	-1.8	2.1	0.0	0.0	0.0
Own work capitalised	0.1	0.0	0.0	0.2	0.0	0.0	0.0
Total Sales	177.4	223.6	231.2	269.7	348.0	330.0	346.5
Material expenses	97.0	123.9	123.7	144.3	194.1	183.2	190.6
Gross profit	80.4	99.7	107.4	125.4	153.9	146.9	155.9
<i>Gross profit margin</i>	<i>45.7 %</i>	<i>44.2 %</i>	<i>46.1 %</i>	<i>46.9 %</i>	<i>44.2 %</i>	<i>44.5 %</i>	<i>45.0 %</i>
Personnel expenses	48.4	58.3	60.5	67.5	78.3	75.9	78.7
Other operating income	16.1	6.9	25.9	7.4	18.0	0.3	0.2
Other operating expenses	26.9	33.3	38.3	39.9	48.5	42.9	44.4
EBITDA adj.	8.6	14.3	17.6	24.6	33.0	30.0	34.5
<i>Margin</i>	<i>4.9 %</i>	<i>6.4 %</i>	<i>7.6 %</i>	<i>9.2 %</i>	<i>9.5 %</i>	<i>9.1 %</i>	<i>10.0 %</i>
EBITDA	21.1	15.0	34.5	25.4	45.1	28.4	33.1
<i>Margin</i>	<i>12.0 %</i>	<i>6.7 %</i>	<i>14.8 %</i>	<i>9.5 %</i>	<i>13.0 %</i>	<i>8.6 %</i>	<i>9.6 %</i>
Depreciation of fixed assets	7.3	10.7	13.0	19.1	22.6	20.8	21.1
EBITA	13.8	4.3	21.5	6.3	22.5	7.6	12.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.2	0.2	0.2
Goodwill amortisation	0.0	0.0	1.6	0.3	0.0	0.0	0.0
EBIT	13.6	4.3	20.0	6.0	22.3	7.4	11.8
<i>Margin</i>	<i>7.7 %</i>	<i>1.9 %</i>	<i>8.6 %</i>	<i>2.2 %</i>	<i>6.4 %</i>	<i>2.2 %</i>	<i>3.4 %</i>
EBIT adj.	2.9	6.4	8.9	13.3	17.9	16.4	20.8
Interest income	0.1	0.1	0.3	0.2	0.0	0.0	0.0
Interest expenses	2.0	2.0	2.8	2.4	2.5	2.5	2.3
Other financial income (loss)	0.5	0.7	2.7	2.4	1.7	1.8	1.8
EBT	12.1	2.4	17.5	5.1	21.5	6.7	11.3
<i>Margin</i>	<i>6.9 %</i>	<i>1.1 %</i>	<i>7.5 %</i>	<i>1.9 %</i>	<i>6.2 %</i>	<i>2.0 %</i>	<i>3.3 %</i>
Total taxes	-0.5	-0.4	1.0	0.4	6.5	2.0	3.4
Net income from continuing operations	12.5	2.8	16.5	4.7	15.1	4.7	7.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	12.5	2.8	16.5	4.7	15.1	4.7	7.9
Minority interest	0.0	0.0	-0.1	-0.4	0.0	0.0	0.0
Net income	12.5	2.8	16.6	5.2	15.1	4.7	7.9
<i>Margin</i>	<i>7.1 %</i>	<i>1.3 %</i>	<i>7.1 %</i>	<i>1.9 %</i>	<i>4.3 %</i>	<i>1.4 %</i>	<i>2.3 %</i>
Number of shares, average	4.0	4.0	4.0	4.2	4.4	4.4	4.4
EPS	3.14	0.71	4.15	1.24	3.43	1.07	1.80
EPS adj.	1.26	1.15	1.51	2.53	2.73	2.50	3.24


*Adjustments made for:

Guidance: 2022: sales of EUR 335m to EUR 350m and adj. EBITDA margin of 8.0% to 9.0%

Financial Ratios


	2018	2019	2020	2021	2022e	2023e	2024e
Total Operating Costs / Sales	88.8 %	92.4 %	84.4 %	91.4 %	87.0 %	91.4 %	90.4 %
Operating Leverage	-2.9 x	-2.4 x	112.3 x	-4.8 x	9.1 x	12.9 x	11.9 x
EBITDA / Interest expenses	10.8 x	7.7 x	12.4 x	10.6 x	18.0 x	11.3 x	14.4 x
Tax rate (EBT)	-4.0 %	-16.3 %	5.9 %	7.5 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	23.8 %	105.9 %	24.2 %	74.8 %	29.2 %	93.5 %	66.5 %

Sales, EBITDA in EUR m




Source: Warburg Research

Operating Performance in %



Source: Warburg Research

Performance per Share



Source: Warburg Research


Consolidated balance sheet

In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Assets							
Goodwill and other intangible assets	6.6	6.9	2.2	34.0	34.2	34.3	34.4
thereof other intangible assets	6.3	6.8	2.2	23.6	23.8	23.9	24.0
thereof Goodwill	0.2	0.2	0.0	10.4	10.4	10.4	10.4
Property, plant and equipment	59.7	90.7	82.1	85.0	70.9	59.1	47.0
Financial assets	8.4	7.0	5.9	8.0	38.0	38.0	38.0
Other long-term assets	3.4	10.3	5.8	7.6	7.6	7.6	7.6
Fixed assets	78.0	115.0	96.1	134.6	150.6	139.0	126.9
Inventories	27.0	30.5	27.5	40.4	38.7	36.7	38.5
Accounts receivable	18.5	21.8	16.6	25.7	23.8	22.6	23.7
Liquid assets	28.8	25.1	36.3	41.4	30.1	45.0	58.6
Other short-term assets	7.8	9.1	22.0	26.0	25.9	26.5	26.4
Current assets	82.1	86.4	102.4	133.4	118.5	130.8	147.2
Total Assets	160.1	201.3	198.5	268.0	269.1	269.7	274.1
Liabilities and shareholders' equity							
Subscribed capital	4.0	4.0	4.0	4.4	4.4	4.4	4.4
Capital reserve	5.1	5.1	5.3	15.7	15.7	15.7	15.7
Retained earnings	0.0	0.0	0.0	0.0	11.6	12.9	16.7
Other equity components	57.7	57.7	70.9	73.0	73.0	73.0	73.0
Shareholders' equity	66.8	66.8	80.2	93.1	104.6	105.9	109.8
Minority interest	0.1	0.2	0.1	5.2	5.2	5.2	5.2
Total equity	66.9	67.0	80.3	98.2	109.8	111.1	114.9
Provisions	9.5	18.5	16.8	18.9	18.9	18.9	18.9
thereof provisions for pensions and similar obligations	2.9	9.2	9.0	9.0	9.0	9.0	9.0
Financial liabilities (total)	62.8	88.4	78.0	108.7	101.4	101.4	101.4
Short-term financial liabilities	27.4	35.1	22.5	32.2	25.0	25.0	25.0
Accounts payable	6.7	11.7	9.2	17.0	13.7	13.0	13.6
Other liabilities	14.2	15.8	14.2	25.3	25.3	25.3	25.3
Liabilities	93.3	134.4	118.2	169.8	159.3	158.6	159.2
Total liabilities and shareholders' equity	160.1	201.3	198.5	268.0	269.1	269.7	274.1


Financial Ratios

	2018	2019	2020	2021	2022e	2023e	2024e
Efficiency of Capital Employment							
Operating Assets Turnover	1.8 x	1.7 x	2.0 x	2.0 x	2.9 x	3.1 x	3.6 x
Capital Employed Turnover	1.7 x	1.6 x	1.8 x	1.5 x	1.8 x	1.9 x	2.1 x
ROA	16.0 %	2.5 %	17.2 %	3.8 %	10.0 %	3.4 %	6.2 %
Return on Capital							
ROCE (NOPAT)	16.2 %	4.1 %	13.9 %	3.6 %	8.6 %	2.8 %	4.8 %
ROE	20.2 %	4.2 %	22.5 %	5.9 %	15.2 %	4.5 %	7.4 %
Adj. ROE	8.1 %	6.8 %	8.2 %	12.1 %	12.1 %	10.4 %	13.2 %
Balance sheet quality							
Net Debt	36.8	72.6	50.8	76.3	80.3	65.4	51.8
Net Financial Debt	34.0	63.4	41.8	67.3	71.3	56.4	42.8
Net Gearing	55.1 %	108.4 %	63.3 %	77.7 %	73.1 %	58.9 %	45.1 %
Net Fin. Debt / EBITDA	160.9 %	422.0 %	121.2 %	264.9 %	158.1 %	199.1 %	129.2 %
Book Value / Share	16.8	16.8	20.1	21.2	23.8	24.1	25.0
Book value per share ex intangibles	15.1	15.1	19.6	13.4	16.0	16.3	17.1


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Net income	12.5	2.8	16.5	4.7	15.1	4.7	7.9
Depreciation of fixed assets	7.5	10.7	13.0	19.4	22.6	20.8	21.1
Amortisation of goodwill	0.0	0.0	1.6	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.2	0.2	0.2
Increase/decrease in long-term provisions	0.3	0.8	-1.3	-1.4	0.0	0.0	0.0
Other non-cash income and expenses	-17.5	-3.3	-22.4	-3.3	0.0	0.0	0.0
Cash Flow before NWC change	2.8	11.1	7.3	19.5	37.9	25.7	29.2
Increase / decrease in inventory	-1.8	3.5	0.4	-6.8	1.7	2.0	-1.8
Increase / decrease in accounts receivable	0.2	-0.5	1.4	-1.2	1.9	1.2	-1.1
Increase / decrease in accounts payable	-2.3	0.3	-1.7	4.2	-3.3	-0.7	0.6
Increase / decrease in other working capital positions	1.4	-10.5	3.2	-3.2	0.0	0.0	0.0
Increase / decrease in working capital (total)	-2.5	-7.2	3.3	-7.1	0.3	2.5	-2.3
Net cash provided by operating activities [1]	0.3	3.9	10.6	12.4	38.2	28.2	26.9
Investments in intangible assets	-0.7	-0.5	-0.2	-0.6	-0.3	-0.3	-0.3
Investments in property, plant and equipment	-6.3	-8.5	-7.2	-9.7	-8.5	-9.0	-9.0
Payments for acquisitions	-12.3	-13.4	-0.1	-29.2	0.0	0.0	0.0
Financial investments	0.0	-1.1	0.3	0.0	-30.0	0.0	0.0
Income from asset disposals	6.9	3.8	19.9	16.4	0.0	0.0	0.0
Net cash provided by investing activities [2]	-9.8	-19.0	13.9	-18.9	-38.8	-9.3	-9.3
Change in financial liabilities	6.2	13.8	-4.2	0.5	-7.2	0.0	0.0
Dividends paid	-4.0	-3.0	-3.0	-4.0	-3.4	-4.0	-4.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.1	0.2	10.8	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	2.2	10.8	-7.0	7.3	-10.6	-4.0	-4.0
Change in liquid funds [1]+[2]+[3]	-7.3	-4.3	17.5	0.9	-11.2	14.9	13.6
Effects of exchange-rate changes on cash	0.0	0.0	0.1	-0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	17.1	24.6	42.6	43.4	30.1	45.0	58.6

Financial Ratios

	2018	2019	2020	2021	2022e	2023e	2024e
Cash Flow							
FCF	-4.1	-4.6	4.3	6.4	29.4	18.9	17.6
Free Cash Flow / Sales	-2.3 %	-2.0 %	1.9 %	2.4 %	8.5 %	5.7 %	5.1 %
Free Cash Flow Potential	21.6	15.4	33.4	25.0	38.6	26.3	29.7
Free Cash Flow / Net Profit	-32.8 %	-162.4 %	26.0 %	123.9 %	195.1 %	401.1 %	222.5 %
Interest Received / Avg. Cash	0.3 %	0.3 %	0.8 %	0.4 %	0.1 %	0.1 %	0.0 %
Interest Paid / Avg. Debt	3.5 %	2.6 %	3.3 %	2.6 %	2.4 %	2.5 %	2.3 %
Management of Funds							
Investment ratio	4.0 %	4.0 %	3.2 %	3.9 %	2.5 %	2.8 %	2.7 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	93.2 %	84.8 %	50.7 %	53.0 %	38.6 %	44.4 %	43.6 %
Avg. Working Capital / Sales	20.4 %	17.6 %	16.2 %	15.7 %	14.1 %	14.4 %	13.7 %
Trade Debtors / Trade Creditors	275.5 %	186.1 %	181.6 %	151.6 %	173.7 %	173.8 %	174.3 %
Inventory Turnover	3.6 x	4.1 x	4.5 x	3.6 x	5.0 x	5.0 x	5.0 x
Receivables collection period (days)	38	35	26	35	25	25	25
Payables payment period (days)	25	34	27	43	26	26	26
Cash conversion cycle (Days)	115	91	80	94	72	72	73


CAPEX and Cash Flow

in EUR m




Source: Warburg Research

Free Cash Flow Generation



Source: Warburg Research

Working Capital



Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Blue Cap	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0JM2M1.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	162	75
Hold	44	20
Sell	6	3
Rating suspended	4	2
Total	216	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	45	80
Hold	8	14
Sell	1	2
Rating suspended	2	4
Total	56	100

PRICE AND RATING HISTORY BLUE CAP AS OF 03.11.2022


Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
Head of Equities mrode@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Stefan Augustin +49 40 309537-168
Cap. Goods, Engineering saugustin@warburg-research.com

Jan Bauer +49 40 309537-155
Renewables jbauer@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Dr. Christian Ehmann +49 40 309537-167
BioTech, Life Science cehmann@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Mustafa Hidir +49 40 309537-230
Automobiles, Car Suppliers mhidir@warburg-research.com

Philipp Kaiser +49 40 309537-260
Real Estate, Construction pkaiser@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Simon Stippig +49 40 309537-265
Real Estate, Telco sstippig@warburg-research.com

Cansu Tatar +49 40 309537-248
Cap. Goods, Engineering ctatar@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Marc Niemann +49 40 3282-2660
Head of Equity Sales, Germany mniemann@mmwarburg.com

Klaus Schilling +49 69 5050-7400
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Lea Bogdanova +49 69 5050-7411
United Kingdom, Ireland lbogdanova@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom mfritsch@mmwarburg.com

Maximilian Martin +49 69 5050-7413
Austria, Poland mmartin@mmwarburg.com

Christopher Seedorf +49 40 3282-2695
Switzerland cseedorf@mmwarburg.com

Sophie Hauer +49 69 5050-7417
Roadshow/Marketing shauer@mmwarburg.com

Juliane Niemann +49 40 3282-2694
Roadshow/Marketing jniemann@mmwarburg.com

Alicia Schmidt +49 69 5050-7416
Roadshow/Marketing Alicia.Schmidt@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Elyaz Dust +49 40 3282-2702
Sales Trading edust@mmwarburg.com

Michael Ilgenstein +49 40 3282-2700
Sales Trading milgenstein@mmwarburg.com

Marcel Magiera +49 40 3282-2662
Sales Trading mmagiera@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Sales Trading jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg RESP MMWA GO
FactSet www.factset.com

Refinitiv www.refinitiv.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com